At Delphia, we are reimagining the treatment of cancer. We are pioneering activation lethality – a new field of oncology that targets cancer’s surprising vulnerability to oncogene activation. While our approach is bold, it is grounded in the powerful and predictive data of human genetics. We believe it has the potential to create a disruptive paradigm shift on how #cancer is treated. Furthermore, we are excited to build a new class of medicines that have the potential to provide greater and more durable benefit to patients across multiple cancer types. Follow along and learn more here: https://lnkd.in/dNjH6GcR
Delphia Therapeutics
Biotechnology Research
Cambridge, Massachusetts 1,899 followers
Flipping the script on cancer
About us
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Website
-
www.delphiatx.com
External link for Delphia Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
One Kendall Sq
Bldg. 200, Ste. 001
Cambridge, Massachusetts 02139, US